Knowledge Distillery

In this article the authors assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia…

Many pregnant people in the United States have received mRNA COVID-19 vaccines, but data are limited on their safety in pregnancy. The authors of this…

The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein in a…

Vaccinations in multiple sclerosis patients receiving disease-modifying drugs

This review focuses on new evidence supporting the global immunization strategy for MS patients receiving disease-modifying drugs (DMDs), including…

The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein in a…

Many pregnant persons in the United States are receiving messenger RNA (mRNA) COVID-19 vaccines, but data are limited on their safety in pregnancy.

Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the…

The mainstay of control of the COVID-19 pandemic is vaccination against SARS-CoV-2.

In this article the authors report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving…

Whether or not persons who have already been infected SARS-CoV-2 should be vaccinated is unclear.

Interim results from a phase 3 trial of the Moderna mRNA-1273 SARS-CoV-2 vaccine indicated 94% efficacy in preventing COVID-19.